Osiris Therapeutics Md: (NASD: OSIR)

$10.98

0.13 (1.20%)

Volume 143,880

May 22 04:00 PM ET

Zacks Rank: 2-Buy

Zacks Rank	Definition	Annualized Return
#1	Strong Buy	26.6%
#2	Buy	18.71%
#3	Hold	10.12%
#4	Sell	4.32%
#5	Strong Sell	2.16%
S&P	500	9.93%

Overview Quote

            Stock Activity
        
		Day Low - High
		10.75 - 11.24
	
		52wk Low - High
		5.51 - 14.46
	
		Previous Close
		10.85
	
		Avg. Volume
		94,192
	
		Industry
		MED-BIOMED/GENE
	
		Market Cap
		357.23 M
	
		Div - Yield
		0.00 - 0.00
	
		Beta
		0.47
	
		PE (Forward)
		0.00
	
		Current Year Est.
		-0.31
	
		Quarterly Earnings ESP 
		0.00%
	
Earnings ESP (Expected Surprise Prediction) is Zacks' proprietary methodology for determining which stocks have the best chance to surprise with their next earnings announcement. The Earnings ESP shows the percentage difference between the Most Accurate Estimate and the Consensus.

                Premium research
            
		Zacks Rank  Short-Term: 1-3 Months
                                                                
                                                                Zacks #1 Rank Strong Buys
                                                                
                                                            This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below. 

                                                                        Zacks Rank
                                                                        Definition
                                                                        Annualized Return
                                                                    
                                                                        #1
                                                                        Strong Buy
                                                                        26.6%
                                                                    
                                                                        #2
                                                                        Buy
                                                                        18.71%
                                                                    
                                                                        #3
                                                                        Hold
                                                                        10.12%
                                                                    
                                                                        #4
                                                                        Sell
                                                                        4.32%
                                                                    
                                                                        #5
                                                                        Strong Sell
                                                                        2.16%
                                                                    
                                                                        S&P
                                                                        500
                                                                        9.93%
                                                                    
Zacks Rank Education - Learn more about the Zacks Rank
Zacks Rank Home - All Zacks Rank resources in one place
Zacks Premium - The only way to get access to the Zacks Rank
                                                        
		2
Buy

		Zacks Recommendation  Long-Term: 6+ Months
                                                                
                                                                All Outperform Rated Stocks
                                                                
                                                            Zacks Recommendations are an excellent predictor of stock price movement over a 6+ month time frame. The recommendations come from the Zacks Equity Research group which combines the Zacks Rank with the insights from their team of over 50 equity analysts. The result is superior long term stock ratings.
The Zacks Recommendations are split into 3 groups: Buy, Hold and Sell. Our Buy recommendations have generated returns of 34.4% in 2006, and 16.69% in 2007. When Zacks Premium members click on the recommendation it will launch them to the Zacks Equity Research report for the stock.    More on these reports below.

                                                                    Difference Between Zacks Rank and Zacks Recommendation

                                                                    Zacks Equity Research Home
Zacks Premium - The only way to get access to Zacks Recommendations
                                                                
		Neutral
	
		Zacks Industry Rank Which industries are set to outperform or underperform the market? You'll find the answer here. We have broken down all industries into over 200 classifications. Then ranked these industries using the most powerful indicator we know (the Zacks Rank). The higher the industry rank, the better the industry should perform in the future. Once you have found an attractive industry then check out the Rank in Industry to find the best stocks within the industry.
When Zacks Premium members click on the Zacks Industry Rank link they will see the full listing of industries and their current rankings.

                                                                About Zacks Industry Rank

                                                                Zacks Industry Rank - All current industry ranks. 

                                                                Zacks Premium - The only way to get access to the Zacks Industry Rank
                                                            
		96 out of 265
	
		Equity Research Report The Zacks Recommendations and Zacks Target Prices are just two of the valuable resources you'll find in the reports created by the Zacks Equity Research group. When Zacks Premium members click on this link they will taken to a page that gives them access to the Zacks Equity Research report for the stock.

                                        Zacks Equity Research Home
                                        Zacks Premium - The only way to get access to Zacks Recommendations
                                    
Updated as of 05/17/2013

		PREMIUM
	
    (  = Change in last 30 days) 
Get all our stock ratings and recommendations with a Free Trial to Zacks Premium Start Free Trial 
Zacks Premium Home | Zacks Rank Stock Education

                Key Earnings Data
            
                            PE (Forward)
                            NA
                        
                            PEG Ratio
                            NA
                        
                            Current Year Est.
                            -0.31
                        
                            Current Quarter Estimate
                            -0.09
                        
                            Most Accurate Estimate
                            -0.09
                        
                            Earnings ESP 
                            0.00%
                        
                            Next Earnings Report Date
                            08-05-2013
                        
                            EPS Last Year
                            -0.38
                        
                            Expected Earnings Growth
                            NA
                        
Earnings ESP (Expected Surprise Prediction) is Zacks' proprietary methodology for determining which stocks have the best chance to surprise with their next earnings announcement. The Earnings ESP shows the percentage difference between the Most Accurate Estimate and the Consensus.

            Company Description
        
OSIRIS THERAPEUTICS, INC. is a leading stem cell therapeutic company focused on developing and marketing products to treat medical conditions in the inflammatory, orthopedic and cardiovascular areas. Osiris currently markets and sells Osteocel for regenerating bone in orthopedic indications. Prochymal is being evaluated in Phase III clinical trials for three indications, including acute and steroid refractory Graft versus Host Disease and also Crohn's disease, and is the only stem cell therapeutic currently designated by FDA as both an Orphan Drug and Fast Track product. Osiris also has partnered with Genzyme Corporation to develop Prochymal as a medical countermeasure to nuclear terrorism and other radiological emergencies. Osiris is a fully integrated company, having developed capabilities in research, development, manufacturing, marketing and distribution of stem cell products.   
Full OSIR Company Report

        
NYSE data is at least 20 minutes delayed.
NASDAQ data is at least 15 minutes delayed.

            Interactive Java Charting | Fundamental Charts
        
            <a href="#"><img id="dart_image_1" src="http://b7d61a7c6b8c307bf531-a92a66b9587e2a0aa805bd4e70b98407.r95.cf2.rackcdn.com/images/zacks/logos/zacks_logo_230x76.png" width="336" height="280" border="0" alt="" /></a>        
Turn Earnings Surprises into quick profits.
 
OSIR Chart  by YCharts

Earnings Estimates

	Current Qtr (06/2013)	Next Qtr (09/2013)	Current Year (12/2013)	Next Year (12/2014)
Average Estimate	-0.09	-0.08	-0.31	-0.36
Number of Estimates	1	1	2	1
Low Estimate	-0.09	-0.08	-0.33	-0.36
High Estimate	-0.09	-0.08	-0.28	NA
Year Ago EPS	-0.13	-0.09	-0.34	-0.31
EPS Growth	30.77%	11.11%	10.29%	-18.03%

More OSIR Estimates

Average Earnings Estimates for OSIR

EPS Growth for OSIR

Industry Analysis

Name	Symbol	Previous Close
OSIRIS THERAPTC	OSIR	10.85
AETERNA ZENTARS	AEZS	2.08
ANIKA THERAPEUT	ANIK	14.45
GENTIUM SPA-ADR	GENT	8.90
AASTROM BIOSCI	ASTM	0.57
ACHILLION PHARM	ACHN	7.75
ADDEX THERA LTD	ADDXF	6.94
AFFYMAX INC	AFFY	1.45
ALEXION PHARMA	ALXN	102.67
ALKERMES INC	ALKS	31.98

Sector:Medical>> Industry:MED-BIOMED/GENE

COMPARE TICKER vs. Its Peers

Zacks Commentary

Pipeline Progress at Gilead

May 16, 2013

Osiris Loss In-Line with Expectations

May 08, 2013

Loss at Aegerion Narrower Than Expected

May 03, 2013

Affymetrix Reports Disappointing 1Q

May 02, 2013

Vertex Loss Lower, Kalydeco Outlook Up

May 01, 2013

Double Setback for Gilead

Apr 30, 2013

Geron Narrows Loss; Cuts Jobs

Apr 29, 2013

Biogen's Earnings Surpass Expectations

Apr 25, 2013

More OSIR Zacks Commentary

Financials

EPS TTM	-0.38
Sales	8
Net Income	-13
Price/Earnings	NA
Price/Book	10.56
Price/Cash Flow	NA
Price/Sales	33.18

More OSIR Financials

News

Osiris Therapeutics Q1 net loss up - Datamonitor

May 20, 2013

Post Earnings Update: Osiris Therapeutics Has Climbed 8.1% Higher in Past Week (OSIR) - Comtex Smartrend(R)

May 20, 2013

Shares of Osiris Therapeutics Under Pressure, Down 1.7% - Financial News Network Online - Market Movers

May 20, 2013

Earnings Flashback: Since Reporting Quarterly Results 1 Week Ago Osiris Therapeutics Is Up 8.1% (OSIR) - Financial News Network Online - Earnings Lookback

May 18, 2013

Stock Investors Bid Up Shares of Osiris Therapeutics, Up 2.0% - Financial News Network Online - Market Movers

May 15, 2013

Osiris Therapeutics Releases 1Q 2013 Results - Close-Up Media

May 10, 2013

Position Yourself for Big Returns in the Stem Cell Space: Jason Kolbert - Kapitall

May 10, 2013

Is the Golden Age of Blockbusters Over? - TheMotleyFool

May 8, 2013

See All News Stories on OSIR

Broker Recommendations

Current ABR	2.50
ABR (Last Week)	2.50
# of recs in ABR	2
Average Target Price	8.50
Industry Rank by ABR	96 out of 265
Rank in Industry	4 out of 157

More OSIR Broker Recommendations

Day Low - High	10.75 - 11.24
52wk Low - High	5.51 - 14.46
Previous Close	10.85
Avg. Volume	94,192
Industry	MED-BIOMED/GENE
Market Cap	357.23 M
Div - Yield	0.00 - 0.00
Beta	0.47
PE (Forward)	0.00
Current Year Est.	-0.31
Quarterly Earnings ESP	0.00%

PE (Forward)	NA
PEG Ratio	NA
Current Year Est.	-0.31
Current Quarter Estimate	-0.09
Most Accurate Estimate	-0.09
Earnings ESP	0.00%
Next Earnings Report Date	08-05-2013
EPS Last Year	-0.38
Expected Earnings Growth	NA

Username: Password:

Remember me [?]

Osiris Therapeutics Md: (NASD: OSIR)

$10.98

0.13 (1.20%)

Volume 143,880

May 22 04:00 PM ET

Stock Activity

Premium research

Zacks Rank Short-Term: 1-3 Months

Zacks Recommendation Long-Term: 6+ Months

Zacks Industry Rank

Equity Research Report

Key Earnings Data

Company Description

Earnings Estimates

Industry Analysis

Sector:Medical>> Industry:MED-BIOMED/GENE

Zacks Commentary

Financials

News

Broker Recommendations